Clinical trials: Death; Neonatal
Perinatal Death, Neonatal Death
Verbal Autopsy of Maternal Deaths, Stillbirths, and Neonatal Deaths in BetterBirth
The purpose of this study is to conduct Verbal Autopsies of deaths ( stillbirths and neonatal deaths together) identified in the BetterBirth trial to identify their potential causes, timing, and social determinants.
- Conditions
- Perinatal Death, Neonatal Death, Stillbirth
- Trial name
- NCT03213509
- Testing
- Interview (Social and Verbal Autopsy)
- Where
- India
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)
Congenital Heart Defect
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease
Genetically inherited heart diseases (familial cardiopathies) are conditions affecting the heart passed on to family members by abnormalities in genetic information.
- Trial name
- NCT00027196
- Where
- United States
- Volunteers
- 9,999,999 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pregnancy Related Complications
PRONTO: Obstetric and Neonatal Emergency Training Program: A Cluster-Randomized Trial to Measure Impact
Rates and causes of maternal mortality in Mexico have dropped only slightly; thus, reaching the internationally established Millennium Development Milestones (MDM) is still a distant goal.
- Trial name
- PRONTO (NCT01477554)
- Testing
- PRONTO training
- Volunteers
- 24 people
- Sponsor
- Instituto Nacional de Salud Publica, Mexico
Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome
Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
The Hearts in Rhythm Organization (HiRO) is a national network of Canadian researchers/clinicians, working towards a better understanding of the rare genetic causes of sudden cardiac death (SCD).
- Conditions
- Sudden Cardiac Arrest, Sudden Arrhythmic Death Syndrome, Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), Long QT Syndrome (LQTS)
- Trial name
- HiRO (NCT04189822)
- Where
- Canada
- Volunteers
- 10,000 people
- Sponsor
- University of British Columbia
Premature Birth, NEUROPROTECTION
Magnesium Sulphate Neuroprotective Strategies for Preterm Deliveries
A Cochrane systematic review has confirmed that fetal exposure to magnesium sulphate given before preterm birth has a neuroprotective role.
- Conditions
- Premature Birth, NEUROPROTECTION, MAGNESIUM SULPHATE, Cerebral Palsy
- Trial name
- NCT05674565
- Testing
- Magnesium sulfate loading with maintenance dose, Magnesium sulfate loading dose only
- Where
- Egypt
- Volunteers
- 336 people
- Sponsor
- Zagazig University
Mucopolysaccharidosis II
Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)
The purpose of this study is to determine whether the administration of iduronate-2-sulfatase enzyme in a weekly or every other week therapy frequency is safe and efficacious in patients with MPS II.
- Trial name
- NCT00069641
- Testing
- Iduronate-2-sulfatase enzyme replacement therapy
- Where
- 9 sites in United States, Brazil and 2 more
- Volunteers
- 96 people
- Sponsor
- Shire
Wolff-Parkinson-White Syndrome, Sudden Cardiac Death
Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With WPW Pattern
Patients with preexcitation are at risk for sudden cardiac death. The pathogenesis is a rapid antegrade conduction of atrial fibrillation over the accessory pathway to the ventricle resulting in ventricular fibrillation.
- Conditions
- Wolff-Parkinson-White Syndrome, Sudden Cardiac Death, Risk Stratification
- Trial name
- NCT03207373
- Testing
- Stress test (ECG)
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Christian Balmer
Child Mortality, Maternal Mortality (All Cause)
MNCH Programming in Southwest Uganda Maternal and Child Health In Bushenyi and Rubirizi Districts, UGANDA
The investigators will assess whether in Bushenyi District in southwestern Uganda, a two year intervention providing comprehensive MNCH programming will: Reduce morbidity and mortality for children under five years old and…
- Trial name
- HCUM (NCT01571765)
- Testing
- MNCH programming in health district
- Where
- Uganda
- Volunteers
- 10,985 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Small for Gestational Age at Delivery, Hypoxic-Ischemic Encephalopathy
Umbilical Cord Abnormalities in the Prediction of Adverse Pregnancy Outcomes
The objective of our study is to investigate the association of umbilical cord abnormalities with adverse pregnancy outcomes. The umbilical cord parameters that will be investigated as part of this study include the umbilical…
- Conditions
- Small for Gestational Age at Delivery, Hypoxic-Ischemic Encephalopathy, Stillbirth, Admission to Neonatal Unit
- Trial name
- ULOOP (NCT05901688)
- Testing
- Umbilical cord measurements & observations
- Where
- United Kingdom
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Medway NHS Foundation Trust
Stillbirth
Revealed Versus Concealed Cerebroplacental Ratio
The purpose of this study is to evaluate the role of an integrated strategy at selecting fetuses for delivery at term based on a combination of fetal biometry and cerebroplacental ratio (CPR) to reduce stillbirth rate and adverse…
- Trial name
- NCT02907242
- Testing
- Revealment
- Where
- 9 sites in Chile, Czechia and 4 more
- Volunteers
- 11,582 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Myocardial Infarction, Dilated Cardiomyopathy
Arrhythmia Prediction Trial
Patients with Ischaemic and Dilated Cardiomyopathy, face an increased risk for Arrhythmic Sudden Cardiac Death. The purpose of this study is to estimate the performance of Modern Non-Invasive Indices and the performance of…
- Conditions
- Myocardial Infarction, Dilated Cardiomyopathy, Heart Failure
- Trial name
- APRET (NCT02175836)
- Where
- Greece
- Volunteers
- 500 people
- Sponsor
- University of Athens
Hunter Syndrome
A Safety and Dose Ranging Study of Idursulfase (Intrathecal) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Hunter Syndrome Who Have Central Nervous System Involvement and Are Receiving Treatment With Elaprase®
Elaprase (idursulfase), a large molecular protein, is not expected to cross the blood brain barrier at therapeutic levels when administered intravenously.
- Trial name
- NCT00920647
- Testing
- Control, Idursulfase IT (1 mg), Idursulfase IT (10 mg)
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Shire
Brain Injuries, Congenital Heart Disease
Protecting Brains and Saving Futures - the PBSF Protocol
Background: Multiple neonatal disorders are associated with risks of neurological injury. Thus, management of these infants should involve a coordinated approach to permit early diagnosis with improved clinical care.
- Conditions
- Brain Injuries, Congenital Heart Disease, Newborn Morbidity, Intraventricular Hemorrhage
- Trial name
- PBSF (NCT03786497)
- Where
- 2 sites in Brazil
- Volunteers
- 2,268 people
- Sponsor
- Protecting Brains Saving Futures
Sudden Unexplained Death Syndrome, Sudden Unexplained Death in Childhood
Sudden Unexplained Death in Childhood (SUDC) Registry
The purpose is to increase the understanding of the characteristics, circumstances, medical histories and pathologies of children from ages 11 months through 18 years who have died suddenly and unexpectedly, and in some…
- Trial name
- SUDC (NCT03109197)
- Testing
- Biospecimin Collection
- Where
- United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Stillbirth, Fetal Death
Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Fetal growth restriction during pregnancy represents one of the biggest risk factors for stillbirth (Gardosi et al, 2013), with 'about one in three term, normally formed antepartum stillbirths are related to abnormalities of…
- Conditions
- Stillbirth, Fetal Death, Fetal Growth Retardation, Small for Gestational Age
- Trial name
- OxGRIP (NCT03662178)
- Where
- United Kingdom
- Volunteers
- 56,000 people, healthy volunteers welcome
- Sponsor
- Oxford University Hospitals NHS Trust
Prenatal Care
Group Antenatal Care: The Power of Peers for Increasing Skilled Birth Attendance in Achham, Nepal
In rural Nepal, the major drivers of underutilization of skilled birth attendance are poverty, poor social support and inadequate birth planning.
- Trial name
- NCT02330887
- Testing
- Group Antenatal Care, Individual Antenatal Care
- Where
- Nepal
- Volunteers
- 2,184 people, healthy volunteers welcome
- Sponsor
- Possible
Inherited Metabolic Diseases, Lysosomal Storage Disorders
ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease.
- Conditions
- Inherited Metabolic Diseases, Lysosomal Storage Disorders, Peroxisomal Storage Diseases, Inborn Errors of Metabolism
- Trial name
- UCBT-002 (NCT00654433)
- Testing
- ALD-101
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aldagen
Primary Immune Deficiency
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections.
- Trial name
- NCT00246857
- Where
- 8 sites in United States, Turkey (Türkiye)
- Volunteers
- 5,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Preeclampsia, Intrauterine Growth Restriction
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.
Preeclampsia (PE) affects ~5% of pregnancies. Although improved obstetrical care has significantly diminished associated maternal mortality, PE remains a leading cause of maternal morbidity and mortality in the world.
- Conditions
- Preeclampsia, Intrauterine Growth Restriction, Maternal Hypertension, Neonatal Outcome
- Trial name
- PE37 (NCT04766866)
- Testing
- sFlt1/PlGF screening in maternal blood at 35 to 36.6 weeks of gestation
- Where
- 21 sites in Belgium, Colombia and 7 more
- Volunteers
- 9,132 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
MPS II, Mucopolysaccharidosis II
MPS II Immunophenotyping
The purpose of this study is to investigate how participant's body's immune system responds to idursulfase, an enzyme replacement therapy (ERT) and find out which types of immune cells are involved in causing untoward responses…
- Conditions
- MPS II, Mucopolysaccharidosis II, Hunter Syndrome
- Trial name
- NCT04976231
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University